Last reviewed · How we verify
NCT02192489
A Phase 2 Study With CC-220 in Skin Sarcoidosis
Phase 2 trial testing CC-220 0.3 mg Daily in Sarcoidosis. Withdrawn.
30 June 2017
Quick facts
| Lead sponsor | Celgene |
|---|---|
| Phase | Phase 2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | single group |
| Masking | quadruple |
| Primary purpose | treatment |
| Start date | 1 November 2014 |
| Primary completion | 30 June 2017 |
| Estimated completion | 30 June 2017 |
Drugs / interventions tested
- CC-220 0.3 mg Daily — full drug profile →
- CC-220 0.6mg Daily — full drug profile →
- Placebo
Conditions studied
- Sarcoidosis — all drugs for Sarcoidosis →
Sponsor
Celgene — full company profile →
Who can join
18 and older, any sex, with Sarcoidosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of oral CC-220 in adult subjects with chronic cutaneous sarcoidosis.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Ikaros Proteins in Tumor: Current Perspectives and New Developments.
Xia R, Cheng Y, Han X, Wei Y, et al · · 2021 · cited 12× · PMID 34950704 · DOI 10.3389/fmolb.2021.788440
Verify or expand the search:
- PubMed search for NCT02192489
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Sarcoidosis
Currently open trials in the same condition.
- NCT07498842 — Corticosteroid Tapering in Sarcoidosis · NA · recruiting
- NCT07073963 — Virtual Patient Groups for Sarcoidosis Associated Fatigue · NA · recruiting
- NCT07384897 — Immune Cells Role in Lung Cancer and Their Use in Anticancer Immunotherapies and Inflammatory Lung Disease · NA · recruiting
- NCT06636487 — Expand Pulmonary Rehabilitation to Other Chronic Respiratory Diseases Than COPD · NA · active not recruiting
- NCT06576505 — Immunological Mechanisms in Sarcoidosis · recruiting
Other Celgene trials
Trials by the same sponsor.
- NCT07242781 — A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult M · Phase 1 · recruiting
- NCT06988488 — A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide · Phase 1, PHASE2 · recruiting
- NCT06911502 — A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Ch · Phase 3 · recruiting
- NCT06808984 — Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants W · Phase 2 · recruiting
- NCT06782490 — A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spastici · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02192489 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Celgene
- Last refreshed: 12 November 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02192489.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing